Iris Friedli, Senior Director MR Imaging at Antaros Medical, will be presenting next week at the 8th Annual Chronic Kidney Disease (CKD) Drug Development Summit. Iris will be discussing how magnetic resonance imaging (MRI)-based biomarkers can be integrated into clinical trials to provide valuable insights into disease pathophysiology, drug mode of action, and treatment effects.
Chronic kidney disease (CKD) and diabetic kidney disease (DKD) are worldwide healthcare problems with rising prevalence. Currently established biomarkers are limited in the insights they can provide, creating an unmet need for non-invasive biomarkers that can provide early, mechanistic insights or evidence of treatment effects.
Using the examples of perirenal and renal sinus fat volumes, apparent diffusion coefficient (ADC) and renal arterial resistive index (RARI), Iris will cover how imaging biomarkers can be integrated into clinical trials all the way from small, mechanistic to large, multi-centre as a complement to established biomarkers.
To hear more, join us for Iris’ presentation at teh CKD Summit on Wednesday March 18 @ 9:00 EDT. Her talk is titled ‘Imaging kidney fat and function: biomarkers for understanding CKD’. The CKD Summit takes place from March 16-18 in Boston, MA.